Other ASCO 2018 Highlights – It’s Not All IO

The ASCO annual meeting will stage an upset in the EGFR field in lung cancer, and competition in breast cancer within the CDK4/6 and PI3 kinase inhibitor classes will get tighter. Loxo could once again steal the show with a tissue-agnostic drug, this time targeting RET. 

Digital illustration of Cancer cell in colour background

While the American Society of Clinical Oncology (ASCO) annual meeting, to be held June 1-5 in Chicago, has a long lineup of immune-oncology hits and misses, there’s plenty to stay on top of outside of immunotherapy, as shown by the ASCO preview report from Pharma Intelligence’s Pharma Biomedtracker and Datamonitor Healthcare analysts.

[Editor’s note: See our companion piece for immuno-oncology highlights for ASCO 2018.]

More from Clinical Trials

More from R&D